Trials / Unknown
UnknownNCT04405622
Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.
Toripalimab Combined With Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single center, pilot trial to evaluate the safety and efficacy of toripalimab and gemcitabine in patients with recurrent or metastatic nasopharyngeal carcinoma.
Conditions
- Nasopharyngeal Carcinoma
- Recurrent Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Chemotherapy Effect
- Immunotherapy
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Toripalimab plus gemcitabine | Subjects receive gemcitabine 1000mg/m2 (Day 1 and Day 8) and Toripalimab , 240mg, (Day 1) of each 21 days for at most 6 cycles, followed by Toripalimab 240mg every three weeks (Q3W) maintenance. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision. |
Timeline
- Start date
- 2020-05-30
- Primary completion
- 2023-03-01
- Completion
- 2023-05-01
- First posted
- 2020-05-28
- Last updated
- 2023-02-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04405622. Inclusion in this directory is not an endorsement.